Salvadori M, Tsalouchos A. Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy. World J Nephrol 2018; 7(3): 71-83 [PMID: 29736379 DOI: 10.5527/wjn.v7.i3.71]
Corresponding Author of This Article
Maurizio Salvadori, MD, Professor, Department of Nephrology and Renal Transplantation, Careggi University Hospital, Viale Gaetano Pieraccini, 18, Florence 50139, Italy. maurizio.salvadori1@gmail.com
Research Domain of This Article
Urology & Nephrology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Nephrol. May 6, 2018; 7(3): 71-83 Published online May 6, 2018. doi: 10.5527/wjn.v7.i3.71
Antineutrophil cytoplasmic antibody associated vasculitides with renal involvement: Open challenges in the remission induction therapy
Maurizio Salvadori, Aris Tsalouchos
Maurizio Salvadori, Department of Nephrology and Renal Transplantation, Careggi University Hospital, Florence 50139, Italy
Aris Tsalouchos, Department of Nephrology and Dialysis, Saints Cosmas and Damian Hospital, Pescia 51017, Italy
Author contributions: Salvadori M and Tsalouchos A equally contributed to the manuscript.
Conflict-of-interest statement: No potential conflicts of interest relevant to this article were reported.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Maurizio Salvadori, MD, Professor, Department of Nephrology and Renal Transplantation, Careggi University Hospital, Viale Gaetano Pieraccini, 18, Florence 50139, Italy. maurizio.salvadori1@gmail.com
Telephone: +39-55-597151 Fax: +39-55-597151
Received: February 2, 2018 Peer-review started: February 5, 2018 First decision: March 7, 2018 Revised: March 12, 2018 Accepted: April 18, 2018 Article in press: April 22, 2018 Published online: May 6, 2018
Core Tip
Core tip: Antineutrophil cytoplasmic antibody (ANCA) associated vasculitides with renal involvement, presents as Rapidly Progressive Glomerulonephritis are organ-threatening and potentially life-threatening diseases. Although remission induction immunosuppressive regimens overall have been very successful in the treatment of these conditions, many questions remain unanswered. The still open challenges and questions concern: (1) The choice of the first-line therapy (cyclophosphamide versus rituximab) based on renal function at baseline, new versus relapsed disease, ANCA specificity, tissue injury and safety; (2) the role of plasma exchange in combination with steroid and non steroid agents; and (3) the advent of novel target therapies and strategies.
